Mutlay Sayan, MD
@MutlaySayan
Followers
5K
Following
758
Media
16
Statuses
161
Radiation Oncologist at Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School. Views are my own.
Joined October 2018
Ağustos’ta Nashville’de düzenlenecek #WorldGU25 konferansında konuşmacı olarak yer almaktan onur duyuyorum. Sunumumda prostat kanserinde hassas tedavi yaklaşımlarını nasıl uygulayabileceğimizi ele alacağım—sizleri de aramızda görmekten mutluluk duyarım!. 🔗
0
0
2
Honored to be speaking at #WorldGU25 this August in Nashville. I’ll be talking about how we can apply precision management in prostate cancer care—hope you’ll join us! .🔗 @GUconference @HarvardRadOnc.
What does precision management really mean in prostate cancer today? Hear from Dr. @MutlaySayan at #WorldGU25 as he breaks it down with expert insight and clinical relevance. Aug 21–23 | Nashville, TN | CE-accredited | Up to 11 credits Register:
1
1
14
RT @HarvardRadOnc: Congratulations to our HROP Class of 2025 - excited to see you flourish in the next step of your careers as attendings,….
0
5
0
RT @VedangMurthy: 1️⃣ Elective Regional Nodal Irradiation in Prostate Cancer.👥 With @DrSrinivas_C, @MutlaySayan & @a_dalpra .🎯 We cover rat….
0
19
0
RT @VedangMurthy: During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contr….
0
12
0
RT @yekeduz_emre: ✨Insightful (and must-read) editorial by @MutlaySayan & @DrPaulNguyen in @EUplatinum : . ➡️As ADT shows modest OS benefit….
0
13
0
RT @MikeSerzanMD: 🗣️Prostate Oral Abstract #ASCO25. 👉Abst5000: Dr #TedDeWeese.presenting #CAN2409+prodrug +EBRT +/-ADT in Int/High Risk PCa….
0
7
0
RT @MikeSerzanMD: 🗣️Prostate Oral Abstract #ASCO25. 👉Abst5001: Dr @Prof_Nick_James presenting #MMAI for benefit from ARPI in high risk M0 P….
0
9
0
RT @HarvardRadOnc: .@HarvardRadOnc takes @ESTRO_RT 🇦🇹: Congrats to @MinaBakhtiar presenting on automated pre-treatment tumor burden imaging….
0
3
0
RT @banu_atalar: UROK 2025 has just started! .The Bi-annual meeting of Turkish Society for Radiation Oncology has made a great start with o….
0
3
0
RT @JournalCancer: Revisit this key study during #GU25 validating that a PSA level >0.5 ng/mL after neoadjuvant ADT and before RT is progno….
0
7
0
RT @DrSpratticus: As the great Dr Anthony D’Amico has reminded me throughout my career, focus on lifting up mentees and care for your famil….
0
7
0
RT @MikeSerzanMD: 👥Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease #GU25. 🐺Dr @ChadTangMD presenting Ab….
0
26
0
RT @MikeSerzanMD: 👥Case-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate Cancer #GU25. Pa….
0
6
0
Great to catch up with Derya and Misha at #GU25! Two incredible colleagues and friends whose dedication and passion for advancing prostate cancer care are truly inspiring. Grateful to work alongside them. @Tilki_De @mishabeltran @ASCO @MassGenBrigham @DanaFarber_GU @HarvardRadOnc
1
3
33
Great to reconnect with my amazing mentor and friend from Türkiye at #GUASCO! Always inspiring to learn from him. @DrYukselUrun @ASCO @MassGenBrigham @DanaFarber @HarvardRadOnc @Harvard @AnkaraUni
3
3
33
RT @MikeSerzanMD: 🗣️Prostate Cancer Oral Abstracts #GU25. Dr @EdwinPosadasMD discussing Abs308 and Abs309. 👉RP vs ADT/RT: Patient selectio….
0
3
0
RT @MikeSerzanMD: 🗣️Prostate Cancer Oral Abstracts #GU25. Dr @Soum_Roy_RadOnc presenting Ab 309: 🔪(RP) versus ⚡️(RT) in high-risk prostate….
0
8
0